KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Jul 31, 2026. Filed Sep 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jul 31, 2026 · Filed Sep 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
During the three months ended July 31, 2026, Brian Webster, our Chief Executive Officer and a member of our Board of Directors, and Traci Umberger, our Chief Administrative Officer and General Counsel and a member of our Board of Directors, each adopted a “Rule 10b5-1 trading arrangement”, as such term is defined in Item 408(a) of Regulation S-K. The trading plans were entered into during an open insider trading window and are intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act, and ourpolicies regarding transactions in our securities.
| Name | Date | Action | Expiration Date | Total Shares Subject to Plan |
|---|---|---|---|---|
| Brian Webster | July 21, 2026 | Adoption | August 31, 2027 | 290,000 |
| Traci Umberger | July 21, 2026 | Adoption | October 12, 2027 | 556,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.